EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies

Oliver Blandy, Pierluigi Lembo, Rebecca Folorunso, Karl-Johan Myren iD, Helene Chevrou-Severac, Simu K Thomas iD

Journal of Market Access & Health Policy · 21.05.2026 · 14 (2) · 32

DOI: 10.3390/jmahp14020032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 21.05.2026. Verfasst von Oliver Blandy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clarivate, 70 St Mary Axe, London EC3A 8BE, UK. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world evidence (RWE) can complement clinical trials to inform health technology assessments (HTAs). This study examined the extent to which RWE is considered in HTAs of non-oncology orphan medicinal products across six agencies globally.

Methods

Published European Medicines Agency decisions were reviewed to identify approved non-oncology orphan medicinal products (2018–2023) that included RWE within their submission package, which was anticipated to align with the inclusion of RWE in HTA submissions. Data were extracted from the corresponding HTA reports published by six national agencies (Australia, Canada, France, Germany, Sweden, and the UK).

Results

RWE was included in 105 regulatory submissions and 52.6% of the corresponding HTA reports (range: 29.9% [Germany] to 78.8% [Canada]), nearly 90% of which received a positive decision (range: 44.4% [Australia] to 100.0% [Germany]). RWE was derived from a variety of study designs and commonly supported clinical efficacy across many therapeutic areas.

Conclusions

RWE commonly supports HTAs of recently approved non-oncology orphan medicinal products, strengthening the evidence base and contributing to demonstration of product value.

Schlagwörter

Stichwörter der Autor:innen

health technology assessmentnon-oncology orphan medicinal productsorphan drugorphan medicinerare diseasereal-world datareal-world evidence

Autor:innen und Institutionen

  • Clarivate, 70 St Mary Axe, London EC3A 8BE, UK.
  • Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Forskaren, Hagaplan 4, 11368 Stockholm, Sweden.
  • Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Neuhofstrasse 34, 6340 Baar, Switzerland.
  • Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA.

ORCID-Profile: Karl-Johan Myren, Simu K Thomas

Förderung

  • Alexion, AstraZeneca Rare Disease

Zitieren

APA

Blandy, O., Lembo, P., Folorunso, R., Myren, K. J., Chevrou-Severac, H., & Thomas, S. K. (2026). Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies. Journal of Market Access & Health Policy, 14(2), 32. https://doi.org/10.3390/jmahp14020032

Vancouver

Blandy O, Lembo P, Folorunso R, Myren KJ, Chevrou-Severac H, Thomas SK. Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies. Journal of Market Access & Health Policy. 2026;14(2):32. doi:10.3390/jmahp14020032

BibTeX
@article{Blandy2026,
  author = {Blandy, Oliver and Lembo, Pierluigi and Folorunso, Rebecca and Myren, Karl-Johan and Chevrou-Severac, Helene and Thomas, Simu K},
  title = {Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies},
  journal = {Journal of Market Access & Health Policy},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {32},
  doi = {10.3390/jmahp14020032}
}
Kostenlos starten →